This content is from: Home

GeneDx files 11 IPR petitions against Myriad patents

Genetic testing company GeneDx has turned to the Patent Trial and Appeal Board to try and invalidate 11 of Myriad Genetics patents, in a move that underlines the increasing popularity of inter partes review proceedings with the pharmaceutical industry

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial